Table 1.
Baseline characteristics, CVD history, and all-cause mortality of the study cohort
| General Lifelines population (n = 146 759) | Individuals with erythrocytosis (strict criteria) (n = 408) | P | |
|---|---|---|---|
| Male/female, % | 41.6/58.4 | 45.4/54.7 | .13 |
| Age, y | 44.8 ± 13.1 | 51.5 ± 13.1 | <.001 |
| BMI, kg/m2 | 26.1 ± 4.3 | 27.9 ± 4.9 | <.001 |
| Systolic BP, mm Hg | 125 ± 15 | 135 ± 17 | <.001 |
| Diastolic BP, mm Hg | 74 ± 9 | 78 ± 10 | <.001 |
| Creatinine, µmol/L | 73.5 ± 13.7 | 77.7 ± 15.6 | <.001 |
| Number of medications used | 1 (0-2) | 1 (0-3) | <.001 |
| Use of antihypertensive drugs, % | 12.5 | 24.0 | <.001 |
| Use of drugs for obstructive airway diseases, % | 7.0 | 11.0 | .001 |
| Use of androgens, % | 0.1 | 0.5 | .004 |
| Current smokers, % | 20.7 | 38.2 | <.001 |
| Diabetes, % | 3.4 | 7.8 | <.001 |
| Metabolic syndrome, % | 17.3 | 35.7 | <.001 |
| Family history of CVD, % | 8.9 | 18.2 | <.001 |
| Hb, g/dL | |||
| Male | 15.1 ± 0.9 | 17.9 ± 0.6 | <.001 |
| Female | 13.4 ± 0.9 | 16.2 ± 0.7 | <.001 |
| Hct, % | |||
| Male | 44.7 ± 2.5 | 52.9 ± 1.4 | <.001 |
| Female | 40.5 ± 2.5 | 49.0 ± 1.8 | <.001 |
| MCV, fL | 89.9 ± 4.2 | 92.2 ± 4.3 | <.001 |
| Leukocytes, ×109/L | 6.1 ± 1.8 | 7.4 ± 2.1 | <.001 |
| Leukocytosis, % | 3.0 | 10.0 | <.001 |
| Platelets, ×109/L | 250 ± 57 | 245 ± 74 | .096 |
| Thrombocytosis, % | 1.2 | 2.2 | <.001 |
| Fasting glucose, mmol/L | 5.0 ± 0.8 | 5.2 ± 1.0 | <.001 |
| HbA1c, % | 5.5 ± 0.5 | 5.6 ± 0.5 | <.001 |
| Total cholesterol, mmol/L | 5.1 ± 1.0 | 5.6 ± 1.2 | <.001 |
| LDL cholesterol, mmol/L | 3.2 ± 0.9 | 3.7 ± 1.1 | <.001 |
| HDL cholesterol, mmol/L | |||
| Male | 1.3 ± 0.3 | 1.3 ± 0.3 | .016 |
| Female | 1.6 ± 0.4 | 1.5 ± 0.4 | .001 |
| Triglycerides, mmol/L | 1.2 ± 0.8 | 1.5 ± 0.9 | <.001 |
| Thrombosis, % | 1.7 | 4.2 | <.001 |
| Stroke, % | 0.6 | 0.5 | .24 |
| Myocardial infarction, % | 1.2 | 3.4 | <.001 |
| Composite cardiovascular events, % | 3.3 | 8.6 | <.001 |
| Antithrombotic agent use, % | |||
| Vitamin K antagonists | 0.9 | 3.4 | <.001 |
| Platelet aggregation inhibitors | 3.2 | 8.6 | <.001 |
| Direct factor Xa inhibitors | 0.0 | 0.0 | .83 |
| All-cause mortality, % | 1.9 | 6.4 | <.001 |
Data are given as mean ± standard deviation, median (interquartile range) when not normally distributed, or percentage. Leukocytosis was defined as leukocytes ≥10 × 109/L. Thrombocytosis was defined as a platelet count ≥400 × 109/L.
BP, blood pressure; HDL, high-density lipoprotein; HbA1c, glycated hemoglobin.